ClinicalTrials.gg
CompletedNCT05968482Updated Apr 9, 2025Results posted

Bioavailability and Safety Study Comparing Two Dose Levels of AMZ001 and One Dose Level of Diclofenac Sodium 1% Gel in Healthy Participants

A Phase 1 interventional study of Diclofenac Sodium Gel in Healthy, sponsored by Amzell. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-09.

Sponsored by Amzell · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
74
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The goal of this clinical trial is to compare drug exposure from two different products (AMZ001 and Diclofenac Sodium 1% Gel) in healthy participants on Day 7 after repeated topical administrations for 7 days.

Participants will receive, in a crossover design, three different treatments

  • AMZ001 Low dose
  • AMZ001 High dose
  • Diclofenac Sodium 1% Gel

Safety and tolerability of AMZ001 will be also investigated.

Read the detailed description

On their both knees, participants will apply once daily either low dose of AMZ001 or high dose of AMZ001 for 7 consecutive days. Participants will also apply Diclofenac Sodium 1% Gel as per label information on each knee.

Intensive pharmacokinetic assessment (blood samplings) will be performed on the first day of application (Day 1) as well as on the last day of application (Day 7).

Each participant will receive each of the three treatments in a randomized manner. Between each treatment, participant will not receive any of the three tested therapies between 3 weeks before receiving the next therapy. (washout period)

Participants will stay on the clinical unit only during each period of treatment but not during washout period.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Amzell is the lead sponsor of 5 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male or female participants 18-65 years of age (e.g., in general good physical health, as judged by the Investigator and no abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12-lead (electrocardiogram) or clinical laboratory tests)
  • Has a (BMI) between 18.0 and 35.0 kg/m\^2 (kilogram per square meter) at Screening.
  • In the case of females of ([FCBP) unless surgically sterilized [hysterectomy, bilateral oophorectomy, bilateral tubal ligation] or are for at least 12 months), are using two acceptable forms of (hormonal contraceptives i.e., oral/implant/injectable/transdermal; intrauterine device (IUD) and/or barrier methods [female condom, male condom, diaphragm, cervical cap, spermicide]; note: 2 barrier methods are two acceptable forms of birth control)). Abstinence or partner's vasectomies are acceptable if the female participant agrees to implement two acceptable forms of birth control if her lifestyle/partner changes.
  • Females of child-bearing potential have a negative serum pregnancy test (SPT) at Screening and negative urine pregnancy test (UPT) on Day -1 of each period and at end of treatment (EOT) visit
  • Are free of any systemic or dermatologic disorder and chronic or acute infections, which, in the opinion of the Principal Investigator (PI), will interfere with the study results or increase the risk of adverse events (AEs)
  • Read, understand, and provide signed before any assessment is performed.

Exclusion criteria

Exclusion Criteria:

  • Participant has any visible skin disease, skin lesions, wounds, or a significant amount of hair at the application site (knee)
  • Use of an medicinal product (IMP) within 30 days or 5 half-lives (if known), whichever is longer, of enrollment or during the study.
  • Treated with systemic or local diclofenac within 30 days of enrollment or during the study (except for study IMP)
  • Known to diclofenac, aspirin, Xarelto, coumadin, or other non-steroidal anti-inflammatory drugs (NSAIDs), including Cyclooxygenase-2 (COX-2) inhibitors.
  • Any history of drug hypersensitivity, asthma, urticaria, or other significant allergic diathesis. Participants with uncomplicated seasonal allergic rhinitis can be accepted only if the expected allergy season is clearly outside enrollment / treatment periods.
  • Females who are pregnant and/or lactating
  • Of but not willing to use adequate for the duration of the study
  • Participant is a current smoker and unable to abstain from smoking during the treatment periods.
  • Use of any topical medication, cosmetics, cream, ointments, lotions on the treatment site 1 week prior to enrollment through EOT visit
  • Use of any medication (including over-the-counter medication, dietary supplements, and herbal remedies) within 2 weeks before first scheduled study drug administration or within less than 5 times the elimination half-life of the respective drug (whichever is longer) or is anticipated to require concomitant medication during the 2-week period or at any time throughout the study. Consumption of any drug metabolizing enzyme (e.g., cytochrome P450 3A4 () or other cytochrome P450 enzymes) inducing or inhibiting beverages or food (e.g., broccoli, Brussel sprouts, grapefruit, grapefruit juice, star fruit) within 3 days prior to and during each treatment period
  • Participant has a known or suspected , excluding basal cell cancer unless it is associated with the treatment area.
  • Participant has a positive blood screen for (HIV), surface antigen (HBsAg), antibody (Anti-HCV)
  • Participant has any acute or chronic condition or is using medications, which, in the investigator's opinion, would make it unsafe for the participant to participate in this study, including abnormal laboratory values, vital signs, physical examination findings prior to randomization or during study participation.
  • History or current evidence of renal disease or impaired renal function at screening as indicated by abnormal levels of serum creatinine (greater than (>) 1.43 mg/dL (milligram per deciliter)) or blood urea nitrogen (greater than or equal to (≥) 35 mg/dL) or the presence of clinical significant abnormal urinary constituents (e.g., albuminuria)
  • History or current evidence of ongoing hepatic disease or impaired hepatic function at screening. A participant will be excluded if more than one of the following lab value deviations are found: 1) (AST) (≥ 1.5 (ULN)), alanine aminotransferase (ALT) (≥ 1.5 ULN), 2) Gamma-Glutamyl Transferase (GGT) (≥ 1.5 ULN), alkaline phosphatase (ALP) (≥ 1.5 ULN), 3) total (> 2.00 mg/dL) or creatine kinase (≥ 3 ULN). A single deviation from the above values is acceptable and will not exclude the participant, unless specifically advised by the Investigator.
  • Participant has clinically relevant chronic or acute infectious illnesses or febrile infections within 2 weeks prior to the first scheduled study drug administration
  • Participant has gastrointestinal bleeding issues, e.g., Gastroesophageal Reflux Disease (GERD), Peptic Ulcer Disease (PUD)
  • Participant has a hospital admission or major surgery within 30 days prior to randomization.
  • Participant has a donation or blood collection of more than 1 unit (approximately 450 mL(milliliter)) of blood (or blood products) or acute loss of blood during the 30 days prior to randomization.
  • Participant has a history of alcohol abuse, prescription drug abuse, or illicit drug use within 6 months prior to Screening.
  • Participant meets eligibility criteria, but study is filled
  • Participant who is an investigational site staff member directly involved in the conduct of the study and his/her family members, site staff member otherwise supervised by the Investigator, or participant who is a Amzell B.V. employee directly involved in the conduct of the study
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
74 participants (actual)

Study arms

  • Experimental
    AMZ001 Low dose

    AMZ001 applied once daily for 7 consecutive days

    Drug: Diclofenac Sodium Gel

  • Experimental
    AMZ001 High dose

    AMZ001 applied once daily for 7 consecutive days

    Drug: Diclofenac Sodium Gel

  • Active comparator
    Diclofenac Sodium 1% Gel

    Reference product applied four-times daily for 7 consecutive days

    Drug: Diclofenac Sodium Gel

Interventions

06

What researchers measure

Primary outcomes

  1. Compare Exposure to Diclofenac

    Area under the curve (AUC) from time zero to 24 hours

    Time frame: Day 7

  2. Pharmacokinetic Parameter - Cmax

    Maximum plasma drug concentration (Cmax)

    Time frame: Day 1

Secondary outcomes

  1. Pharmacokinetic Parameter - Cmin

    Minimum plasma drug concentration (Cmin)

    Time frame: Day 7

  2. Pharmacokinetic Parameter - Tmax

    Time to reach maximum plasma concentration (Tmax)

    Time frame: Day 7

  3. Pharmacokinetic Parameter - Ke

    Terminal disposition rate constant (Ke)

    Time frame: Day 7

  4. Pharmacokinetic Parameter - Cavg

    Average plasma concentration (Cavg)

    Time frame: Day 7

  5. Pharmacokinetic Parameter - Tmax

    Time to reach maximum plasma concentration

    Time frame: Day 1

  6. Pharmacokinetic Parameter - Cavg

    Average plasma concentration (Cavg)

    Time frame: Day 1

  7. Local Tolerability

    Incidence of application site reactions according to the terminology of the International Contact Dermatitis Research Group

    Time frame: Day 1 to Day 7

07

Results

Posted Apr 9, 2025

Participant flow

First Crossover Period
Participant flow — First Crossover Period
MilestoneAMZ001 Low / AMZ001 High / DiclofenacDiclofenac/AMZ001 High/AMZ001 LowDiclofenac/AMZ001 Low/AMZ001 HighAMZ001 High/AMZ001 Low/DiclofenacAMZ001 Low/Diclofenac/AMZ001 HighAMZ001 High/Diclofenac/AMZ001 Low
Started121212131312
Completed121211131311
Not completed001001
Withdrew: Withdrawal by subject001000
Withdrew: Adverse event000001
Second Crossover Period
Participant flow — Second Crossover Period
MilestoneAMZ001 Low / AMZ001 High / DiclofenacDiclofenac/AMZ001 High/AMZ001 LowDiclofenac/AMZ001 Low/AMZ001 HighAMZ001 High/AMZ001 Low/DiclofenacAMZ001 Low/Diclofenac/AMZ001 HighAMZ001 High/Diclofenac/AMZ001 Low
Started121211131311
Completed121211131211
Not completed000010
Withdrew: Withdrawal by subject000010
Third Crossover Period
Participant flow — Third Crossover Period
MilestoneAMZ001 Low / AMZ001 High / DiclofenacDiclofenac/AMZ001 High/AMZ001 LowDiclofenac/AMZ001 Low/AMZ001 HighAMZ001 High/AMZ001 Low/DiclofenacAMZ001 Low/Diclofenac/AMZ001 HighAMZ001 High/Diclofenac/AMZ001 Low
Started121211131211
Completed121111131111
Not completed010010
Withdrew: Adverse event000010
Withdrew: Failure to meet continuation criteria010000

Outcome measures

PrimaryCompare Exposure to Diclofenac

Area under the curve (AUC) from time zero to 24 hours

Time frame:
Day 7
Reported as:
Geometric mean · ng*hr/mL
Compare Exposure to Diclofenac
ng*hr/mLAMZ001 Low DoseAMZ001 High DoseDiclofenac Sodium 1% Gel
Compare Exposure to Diclofenac141.5 ± 89.8166.1 ± 90.3202.3 ± 79.4
PrimaryPharmacokinetic Parameter - Cmax

Maximum plasma drug concentration (Cmax)

Time frame:
Day 1
Reported as:
Geometric mean · ng/mL
Pharmacokinetic Parameter - Cmax
ng/mLAMZ001 Low DoseAMZ001 High DoseDiclofenac Sodium 1% Gel
Pharmacokinetic Parameter - Cmax4.66 ± 122.46.22 ± 128.93.85 ± 122.2
SecondaryPharmacokinetic Parameter - Cmin

Minimum plasma drug concentration (Cmin)

Time frame:
Day 7
Reported as:
Geometric mean · ng/mL
Pharmacokinetic Parameter - Cmin
ng/mLAMZ001 Low DoseAMZ001 High DoseDiclofenac Sodium 1% Gel
Pharmacokinetic Parameter - Cmin3.09 ± 96.33.38 ± 90.15.03 ± 80.1
SecondaryPharmacokinetic Parameter - Tmax

Time to reach maximum plasma concentration (Tmax)

Time frame:
Day 7
Reported as:
Median · hr
Pharmacokinetic Parameter - Tmax
hrAMZ001 Low DoseAMZ001 High DoseDiclofenac Sodium 1% Gel
Pharmacokinetic Parameter - Tmax8 (2 to 24)10 (2 to 24)18 (2 to 24)
SecondaryPharmacokinetic Parameter - Ke

Terminal disposition rate constant (Ke)

Time frame:
Day 7
Reported as:
Geometric least squares mean · 1/hr
Pharmacokinetic Parameter - Ke
1/hrAMZ001 Low DoseAMZ001 High DoseDiclofenac Sodium 1% Gel
Pharmacokinetic Parameter - KeNA ± NANA ± NANA ± NA
SecondaryPharmacokinetic Parameter - Cavg

Average plasma concentration (Cavg)

Time frame:
Day 7
Reported as:
Geometric least squares mean · ng/mL
Pharmacokinetic Parameter - Cavg
ng/mLAMZ001 Low DoseAMZ001 High DoseDiclofenac Sodium 1% Gel
Pharmacokinetic Parameter - Cavg5.90 ± 89.86.92 ± 90.38.43 ± 79.4
SecondaryPharmacokinetic Parameter - Tmax

Time to reach maximum plasma concentration

Time frame:
Day 1
Reported as:
Median · hr
Pharmacokinetic Parameter - Tmax
hrAMZ001 Low DoseAMZ001 High DoseDiclofenac Sodium 1% Gel
Pharmacokinetic Parameter - Tmax14 (2 to 24)16 (4 to 24)20 (6 to 24)
SecondaryPharmacokinetic Parameter - Cavg

Average plasma concentration (Cavg)

Time frame:
Day 1
Reported as:
Geometric mean · ng/mL
Pharmacokinetic Parameter - Cavg
ng/mLAMZ001 Low DoseAMZ001 High DoseDiclofenac Sodium 1% Gel
Pharmacokinetic Parameter - Cavg2.59 ± 119.83.48 ± 124.81.60 ± 109.9
SecondaryLocal Tolerability

Incidence of application site reactions according to the terminology of the International Contact Dermatitis Research Group

Time frame:
Day 1 to Day 7
Reported as:
Count of participants · Participants
Local Tolerability
ParticipantsAMZ001 Low DoseAMZ001 High DoseDiclofenac Sodium 1% Gel
no skin reaction626164
doubtful skin reaction777
mild skin erythema141
strong skin erythema100

Adverse events

Collected over From initiation of first period (Day 1) to completion of last period (Day 98). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
AMZ001 Low Dose0/71 (0%)0/71 (0%)7/71 (9.9%)
AMZ001 High Dose0/72 (0%)0/72 (0%)8/72 (11.1%)
Diclofenac Sodium 1% Gel0/72 (0%)0/72 (0%)5/72 (6.9%)
Most frequent other events
Showing 10 of 23
Most frequent other events
EventAMZ001 Low DoseAMZ001 High DoseDiclofenac Sodium 1% Gel
Application site erythemaGeneral disorders0/713/721/72
ErythemaSkin and subcutaneous tissue disorders2/711/720/72
HeadacheNervous system disorders2/710/721/72
Application site hypersensitivityGeneral disorders0/712/720/72
Aphthous ulcerGastrointestinal disorders1/710/720/72
Pain in extremityMusculoskeletal and connective tissue disorders1/710/720/72
Administration site drynessGeneral disorders1/710/720/72
Application site pruritusGeneral disorders1/710/720/72
DiarrhoeaGastrointestinal disorders1/711/720/72
Dry mouthGastrointestinal disorders1/710/720/72

Baseline characteristics

Age, Continuous
Age, Continuous(years)AMZ001 Low/AMZ001 High/DiclofenacDiclofenac/AMZ001 High/AMZ001 LowDiclofenac/AMZ001 Low/AMZ001 HighAMZ001 High/AMZ001 Low/DiclofenacAMZ001 Low/Diclofenac/AMZ001 HighAMZ001 High/Diclofenac/AMZ001 LowTotal
Mean44.0 ± 11.2042.3 ± 14.6936.4 ± 12.3542.3 ± 10.6039.8 ± 11.9841.8 ± 13.4741.1 ± 12.69
Sex: Female, Male
Sex: Female, Male(Participants)AMZ001 Low/AMZ001 High/DiclofenacDiclofenac/AMZ001 High/AMZ001 LowDiclofenac/AMZ001 Low/AMZ001 HighAMZ001 High/AMZ001 Low/DiclofenacAMZ001 Low/Diclofenac/AMZ001 HighAMZ001 High/Diclofenac/AMZ001 LowTotal
Female755107438
Male57736836
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)AMZ001 Low/AMZ001 High/DiclofenacDiclofenac/AMZ001 High/AMZ001 LowDiclofenac/AMZ001 Low/AMZ001 HighAMZ001 High/AMZ001 Low/DiclofenacAMZ001 Low/Diclofenac/AMZ001 HighAMZ001 High/Diclofenac/AMZ001 LowTotal
Hispanic or Latino33584427
Not Hispanic or Latino99759847
Unknown or Not Reported0000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)AMZ001 Low/AMZ001 High/DiclofenacDiclofenac/AMZ001 High/AMZ001 LowDiclofenac/AMZ001 Low/AMZ001 HighAMZ001 High/AMZ001 Low/DiclofenacAMZ001 Low/Diclofenac/AMZ001 HighAMZ001 High/Diclofenac/AMZ001 LowTotal
American Indian or Alaska Native0000000
Asian0010012
Native Hawaiian or Other Pacific Islander1001013
Black or African American66756737
White56477332
More than one race0000000
Unknown or Not Reported0000000
08

Study locations

1 site
  • TKL Research
    Fair Lawn, New Jersey 07410, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2023 to primary completion in Dec 2023, 5 months.

Results were first posted in Apr 2025, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 7, 2023
First posted
Aug 1, 2023
StartActual
Jul 11, 2023
Primary completionActual
Dec 27, 2023
CompletionActual
Dec 2, 2024
Results first posted
Apr 9, 2025
Last update
Apr 9, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 9, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05968482
Lead sponsor
Amzell
Responsible party
Sponsor
First posted
Aug 1, 2023
Start date
Jul 11, 2023
Primary completion
Dec 27, 2023
Completion
Dec 2, 2024
Results posted
Apr 9, 2025
Last update
Apr 9, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Diclofenac Sodium Gel

Start the discussion